Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesAntiangiogenic strategies for treatment of malignant gliomas
Neurotherapeutics, 07/01/09
Chi AS et al. - A review of antiangiogenic strategies for treatment of malignant gliomas (MG) summarizes clinical experience with antiangiogenic therapy in MG pts, major issues for use and development of these agents, and strategies based on initial gains seen with antiangiogenic agents.
Methods- Review of antiangiogenic strategies for treatment of MG
- Studies are ongoing for numerous antiangiogenic agents with diverse mechanisms of action in treatment of GBM pts
- Early clinical trials suggest that antiangiogenic drugs, which target blood vessels of these highly angiogenic tumors, may have clinical benefit in GBM pts
- Antiangiogenic agents have potent antiedema and steroid-sparing effects; emerging data suggest modest improvement in progression-free survival
- Post-treatment with antiangiogenic agents, a major challenge is interpretation of radiographic changes
- Reliable radiographic and biologic markers are lacking to predict which pts benefit from treatment and accurately indicate response and progression during therapy
- Most pts treated with antiangiogenic drugs eventually progress
Related Articles
MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells
Journal of Neuro-Oncology, 11/04/09
Relevance Score: 68%
Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells
European Journal of Cancer, 11/19/09
Relevance Score: 67%
Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma
The Journal of Nuclear Medicine, 11/18/09
Relevance Score: 67%
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Neuro-Oncology, 10/06/09
Relevance Score: 67%
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Neuro-Oncology, 10/06/09
Relevance Score: 67%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiosurgery and whole brain therapy in the treatment of brainstem metastases
Clinical and Translational Oncology, 11/25/09
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2
Virchows Archiv, 11/25/09
Role of caspase 8 as a determinant in trail sensitivity of neuroblastoma cell lines
Pediatric Hematology and Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor